Project details
Total cost:
EUR 202 500EU contribution:
EUR 202 500Coordinated in:
UkraineTopic(s):
MSCA-RISE-2015 - Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE)Call for proposal:
H2020-MSCA-RISE-2015Funding scheme:
MSCA-RISE - Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE)Objective
MATERIALS RESEARCH CENTER
Ukraine
EU contribution: EUR 9 000
YAROSLAVIV VAL/OLISYA GONCHARA STREET, 19/33-A
01034 KIEV
Ukraine
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
UNIVERSITE DE FRANCHE-COMTE
France
EU contribution: EUR 63 000
CLAUDE GOUDIMEL 1
25030 BESANCON
France
Activity type: Higher or Secondary Education Establishments
LATVIJAS UNIVERSITATES CIETVIELU FIZIKAS INSTITUTS
Latvia
EU contribution: EUR 45 000
KENGARAGA IELA 8
LV-1063 RIGA
Latvia
Activity type: Higher or Secondary Education Establishments
TARTU ULIKOOL
Estonia
EU contribution: EUR 27 000
ULIKOOLI 18
50090 TARTU
Estonia
Activity type: Higher or Secondary Education Establishments
https://cordis.europa.eu/project/rcn/199919_en.html
Project News:
Session dedicated to HORIZON-2020-MSCA-RISE project 690853 «Asymmetry of biological membrane: theoretical, experimental and applied aspects» ( assymcurv ), 5th International Conference "Nanobiophysics-2017"
Oleksiy Gogotsi, director of Materials Research Center presented join research on synthesis and biomedical applications of 2D carbides MXenes.

MXenes potential applications include sensors, wound healing materials, and drug delivery systems. A recent study explored how different synthesis methods affect the safety and performance of MXenes. By comparing etching conditions and intercalation strategies, researchers discovered that fine-tuning the surface chemistry of MXenes plays a crucial role in improving biocompatibility. These results provide practical guidelines for developing safer MXenes and bring the field one step closer to real biomedical applications.
Exellent news, our joint patent application with Drexel University on highly porous MAX phase precursor for MXene synthesis published. Congratulations and thanks to all team involved!
Last Call! Have you submitted your abstract for IEEE NAP-2025 yet? Join us at the International Symposium on "The MXene Frontier: Transformative Nanomaterials Shaping the Future" – the largest MXene-focused conference in Europe this year! Final Submission Deadline: May 15, 2025. Don’t miss this exclusive opportunity to showcase your research and engage with world leaders in the MXene field!
We are excited to announce the publication of latest review article on MXenes in Healthcare. This comprehensive review explores the groundbreaking role of MXenes—an emerging class of 2D materials—in revolutionizing the fields of medical diagnostics and therapeutics. Read the full article here: https://doi.org/10.1039/D4NR04853A.
Congratulations and thank you to our collaborators from TU Wien and CEST for very interesting work and making it published! In this work, an upscalable electrochemical MXene synthesis is presented. Yields of up to 60% electrochemical MXene (EC-MXene) with no byproducts from a single exfoliation cycle are achieved.
Congratulations to all collaborators with this interesting joint work!
Thank you to our collaborators for the amazing joint work recently published in Graphene and 2D Nanomaterials about MXene–silk fibroin composite films aiming to develop materials with tunable electronic and thermal properties
Dr. Oleksiy Gogotsi, director of MRC and Carbon-Ukraine, innovative companies that are among the leaders on the world MXene market, visited 2024 MRS Fall Meeting & Exhibit. together with Dr. Maksym Pogorielov, Head of Advanced Biomaterials and Biophysics Laboratory, University of Latvia.
MRC and Carbon-Ukraine team visited the 3rd International MXene conference held at Drexel University on August 5-8, 2024. Conference brought together the best reserchers and leading experts on MXene field. 
Together with colleagues from the University of Latvia, MRC/Carbone Ukraine, Adam Mickiewicz University, University Clinic Essen, and others, we have developed a novel concept involving the binding of antibodies to MXenes. In our research, we utilized anti-CEACAM1 antibodies to develop targeted photo-thermal therapy for melanoma (in vitro), paving the way for future in vivo studies and clinical trials. For the first time, we demonstrate the feasibility of delivering MXenes specifically targeted to melanoma cells, enabling the effective ablation of cancer cells under near-infrared (NIR) light. This new technique opens up vast potential for the application of MXenes in cancer treatment, diagnostics, drug delivery, and many other medical purposes.
